search button
Open Access

Downregulation of miR‑193a‑3p via targeting cyclin D1 in thyroid cancer

  • Authors:
    • Xiao‑Jiao Li
    • Rong Wen
    • Dong‑Yue Wen
    • Peng Lin
    • Deng‑Hua Pan
    • Li‑Jie Zhang
    • Yu He
    • Lin Shi
    • Yong‑Ying Qin
    • Yun‑Hui Lai
    • Jing‑Ni Lai
    • Jun‑Lin Yang
    • Qin‑Qiao Lai
    • Jun Wang
    • Jun Ma
    • Hong Yang
    • Yu‑Yan Pang

  • View Affiliations

  • Published online on: July 8, 2020     https://doi.org/10.3892/mmr.2020.11310
  • Pages: 2199-2218

  • Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Thyroid cancer (TC) is a frequently occurring malignant tumor with a rising steadily incidence. microRNA (miRNA/miR)‑193a‑3p is an miRNA that is associated with tumors, playing a crucial role in the genesis and progression of various cancers. However, the expression levels of miR‑193a‑3p and its molecular mechanisms in TC remain to be elucidated. The present study aimed to probe the expression of miR‑193a‑3p and its clinical significance in TC, including its underlying molecular mechanisms. Microarray and RNA sequencing data gathered from three major databases, specifically Gene Expression Omnibus (GEO), ArrayExpress and The Cancer Genome Atlas (TCGA) databases, and the relevant data from the literature were used to examine miR‑193a‑3p expression. Meta‑analysis was also conducted to evaluate the association between clinicopathological parameters and miR‑193a‑3p in 510 TC and 59 normal samples from the TCGA database. miRWalk 3.0, and the TCGA and GEO databases were used to predict the candidate target genes of miR‑193a‑3p. Gene Ontology, Kyoto Encyclopedia of Genes and Genomes and protein‑protein interaction network enrichment analyses were conducted by using the predicted candidate target genes to investigate the underlying carcinogenic mechanisms. A dual luciferase assay was performed to validate the targeting regulatory association between the most important hub gene cyclin D1 (CCND1) and miR‑193a‑3p. miR‑193a‑3p expression was considerably downregulated in TC compared with in the non‑cancer controls (P<0.001). The area under the curve of the summary receiver operating characteristic was 0.80. Downregulation of miR‑193a‑3p was also significantly associated with age, sex and metastasis (P=0.020, 0.044 and 0.048, respectively). Bioinformatics analysis indicated that a low miR‑193a‑3p expression may augment CCND1 expression to affect the biological processes of TC. In addition, CCND1, as a straightforward target, was validated through a dual luciferase assay. miR‑193a‑3p and CCND1 may serve as prognostic biomarkers of TC. Finally, miR‑193a‑3p may possess a crucial role in the genesis and progression of TC by altering the CCND1 expression.
View Figures
View References

Related Articles

Journal Cover

September-2020
Volume 22 Issue 3

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 3.4
  • Ranked Medicine Research and Experimental
    (total number of cites)
  • CiteScore: 6.9
  • CiteScore Rank: Q2: #98/328 Biochemistry, Genetics and Molecular Biology
  • Source Normalized Impact per Paper (SNIP): 0.721
  • SCImago Journal Rank (SJR): 0.65
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Li XJ, Wen R, Wen DY, Lin P, Pan DH, Zhang LJ, He Y, Shi L, Qin YY, Lai YH, Lai YH, et al: Downregulation of miR‑193a‑3p via targeting cyclin D1 in thyroid cancer. Mol Med Rep 22: 2199-2218, 2020
APA
Li, X., Wen, R., Wen, D., Lin, P., Pan, D., Zhang, L. ... Pang, Y. (2020). Downregulation of miR‑193a‑3p via targeting cyclin D1 in thyroid cancer. Molecular Medicine Reports, 22, 2199-2218. https://doi.org/10.3892/mmr.2020.11310
MLA
Li, X., Wen, R., Wen, D., Lin, P., Pan, D., Zhang, L., He, Y., Shi, L., Qin, Y., Lai, Y., Lai, J., Yang, J., Lai, Q., Wang, J., Ma, J., Yang, H., Pang, Y."Downregulation of miR‑193a‑3p via targeting cyclin D1 in thyroid cancer". Molecular Medicine Reports 22.3 (2020): 2199-2218.
Chicago
Li, X., Wen, R., Wen, D., Lin, P., Pan, D., Zhang, L., He, Y., Shi, L., Qin, Y., Lai, Y., Lai, J., Yang, J., Lai, Q., Wang, J., Ma, J., Yang, H., Pang, Y."Downregulation of miR‑193a‑3p via targeting cyclin D1 in thyroid cancer". Molecular Medicine Reports 22, no. 3 (2020): 2199-2218. https://doi.org/10.3892/mmr.2020.11310